Differentiation of renal oncocytoma from renal cell carcinoma by means of ⁹⁹Tc-Sestamibi SPECT/CT
Author: Tzortzakakis, Antonios
Date: 2021-02-05
Location: Leif Svensson sal, Medical Radiation Physics and Nuclear Medicine, Section for Nuclear Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden
Time: 09.00
Department: Inst för klinisk vetenskap, intervention och teknik / Dept of Clinical Science, Intervention and Technology
View/ Open:
Thesis (7.964Mb)
Abstract
Purpose: An increasing body of literature indicates the beneficial role of [99m]Tc-Sestamibi SPECT/CT in the non-invasive differentiation of renal oncocytoma (RO) from renal cell carcinoma (RCC). This thesis presents a comprehensive approach of [99m]Tc-Sestamibi SPECT/CT examination following the implementation of quantitative tools in addition to visual assessment. An additional aim is to explain the differences in [99m]Tc-Sestamibi uptake among the different RCC subgroups on histometabolomic grounds.
Methods: 57 radiologically detected kidney tumours from 52 patients were included in the present thesis. Each participant underwent a [99m]Tc-Sestamibi SPECT/CT examination before nephrectomy or percutaneous kidney biopsy. Kidney tumours with increased [99m]Tc-Sestamibi uptake were classified as positive (Sestamibi positive). In contrast, those with equal or decreased [99m]Tc-Sestamibi compared to the ipsilateral non-tumoral kidney parenchyma were classified as negative (Sestamibi negative). Following the visual assessment, quantitative SUVmean and SUVmax measurements performed in the examined kidney tumour and the non- tumoral kidney parenchyma that correlated with the histopathological results. Additional immunohistochemical investigation, in situ metabolomics profile characterisation and correlation of mitochondrial content with [99m]Tc-Sestamibi SPECT/CT data, were also performed.
Results: Visual assessment of [99m]Tc-Sestamibi SPECT/CT examination resulted in a sensitivity of 82% whereas, the quantitative assessment showed a sensitivity of 64% regarding the preoperative characterisation of RO. [99m]Tc-Sestamibi SPECT/CT identifies a larger Sestamibi-positive tumour group containing RO, hybrid oncocytic chromophobe tumour (HOCT) and the majority of chromophobe RCC (chRCC). A discriminatory metabolomic signature was identified for Sestamibi positive Birt-Hogg-Dubè-associated HOCT vs other renal oncocytic tumours. Metabolomic differences were also found between Sestamibi positive and negative chRCCs.
Conclusion: Sestamibi positive kidney tumours on SPECT/CT examination are possibly of benign nature. Quantitative assessment with SUV SPECT measurements did not improve the diagnostic performance of [99m]Tc-Sestamibi SPECT/CT. Sestamibi negative kidney tumours should be considered for surgery due to their possibly malignant nature. On the other hand, Sestamibi positive kidney tumours could be suited for biopsy and/or follow up according to surveillance protocols.
Methods: 57 radiologically detected kidney tumours from 52 patients were included in the present thesis. Each participant underwent a [99m]Tc-Sestamibi SPECT/CT examination before nephrectomy or percutaneous kidney biopsy. Kidney tumours with increased [99m]Tc-Sestamibi uptake were classified as positive (Sestamibi positive). In contrast, those with equal or decreased [99m]Tc-Sestamibi compared to the ipsilateral non-tumoral kidney parenchyma were classified as negative (Sestamibi negative). Following the visual assessment, quantitative SUVmean and SUVmax measurements performed in the examined kidney tumour and the non- tumoral kidney parenchyma that correlated with the histopathological results. Additional immunohistochemical investigation, in situ metabolomics profile characterisation and correlation of mitochondrial content with [99m]Tc-Sestamibi SPECT/CT data, were also performed.
Results: Visual assessment of [99m]Tc-Sestamibi SPECT/CT examination resulted in a sensitivity of 82% whereas, the quantitative assessment showed a sensitivity of 64% regarding the preoperative characterisation of RO. [99m]Tc-Sestamibi SPECT/CT identifies a larger Sestamibi-positive tumour group containing RO, hybrid oncocytic chromophobe tumour (HOCT) and the majority of chromophobe RCC (chRCC). A discriminatory metabolomic signature was identified for Sestamibi positive Birt-Hogg-Dubè-associated HOCT vs other renal oncocytic tumours. Metabolomic differences were also found between Sestamibi positive and negative chRCCs.
Conclusion: Sestamibi positive kidney tumours on SPECT/CT examination are possibly of benign nature. Quantitative assessment with SUV SPECT measurements did not improve the diagnostic performance of [99m]Tc-Sestamibi SPECT/CT. Sestamibi negative kidney tumours should be considered for surgery due to their possibly malignant nature. On the other hand, Sestamibi positive kidney tumours could be suited for biopsy and/or follow up according to surveillance protocols.
List of papers:
I. Tzortzakakis A, Gustafsson O, Karlsson M, Ekström-Ehn L, Ghaffarpour R, Axelsson R. Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-Sestamibi SPECT/CT. EJNMMI Research. 2017;7.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Tzortzakakis A, Holstensson M, Hagel E, Karlsson M, Axelsson R. Intra- and Interobserver Agreement of SUV SPECT Quantitative SPECT/CT Processing Software, Applied in Clinical Settings for Patients with Solid Renal Tumors. J Nucl Med Technol. 2019;47:258–62.
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Papathomas T, Tzortzakakis A, Sun N, Erlmeier F, Bozoky B, Kokaraki G, et al. In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on 99mTc-Sestamibi Single Photon Emission Computed Tomography / Computed Tomography Examination. Eur Urol Open Sci. 2020;22:88–96.
Fulltext (DOI)
Pubmed
IV. Antonios Tzortzakakis, Thomas Papathomas, Ove Gustafsson, Stefan Gabrielson, Kiril Trpkov, Linnea Ekström-Ehn, Bela Bozoky, Wanzhong Wang, Alexandros Arvanitis, Maria Holstensson, Mattias Karlsson, Georgia Kokaraki, Eva Hagel, Rimma Axelsson. Differentiation of renal oncocytoma from renal cell carcinoma by means of 99mTc-Sestamibi SPECT/CT. [Manuscript]
I. Tzortzakakis A, Gustafsson O, Karlsson M, Ekström-Ehn L, Ghaffarpour R, Axelsson R. Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-Sestamibi SPECT/CT. EJNMMI Research. 2017;7.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Tzortzakakis A, Holstensson M, Hagel E, Karlsson M, Axelsson R. Intra- and Interobserver Agreement of SUV SPECT Quantitative SPECT/CT Processing Software, Applied in Clinical Settings for Patients with Solid Renal Tumors. J Nucl Med Technol. 2019;47:258–62.
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Papathomas T, Tzortzakakis A, Sun N, Erlmeier F, Bozoky B, Kokaraki G, et al. In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on 99mTc-Sestamibi Single Photon Emission Computed Tomography / Computed Tomography Examination. Eur Urol Open Sci. 2020;22:88–96.
Fulltext (DOI)
Pubmed
IV. Antonios Tzortzakakis, Thomas Papathomas, Ove Gustafsson, Stefan Gabrielson, Kiril Trpkov, Linnea Ekström-Ehn, Bela Bozoky, Wanzhong Wang, Alexandros Arvanitis, Maria Holstensson, Mattias Karlsson, Georgia Kokaraki, Eva Hagel, Rimma Axelsson. Differentiation of renal oncocytoma from renal cell carcinoma by means of 99mTc-Sestamibi SPECT/CT. [Manuscript]
Institution: Karolinska Institutet
Supervisor: Axelsson, Rimma
Co-supervisor: Brismar, Torkel; Holstensson, Maria
Issue date: 2021-01-15
Rights:
Publication year: 2021
ISBN: 978-91-8016-096-4
Statistics
Total Visits
Views | |
---|---|
Differentiation ... | 667 |
Total Visits Per Month
September 2023 | October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | |
---|---|---|---|---|---|---|---|
Differentiation ... | 14 | 32 | 21 | 26 | 20 | 18 | 22 |
File Visits
Views | |
---|---|
Thesis_Antonios_Tzortzakakis.pdf | 297 |
16 December Thesis Tzortzakakis.pdf | 1 |
Top country views
Views | |
---|---|
Sweden | 113 |
United States | 111 |
United Kingdom | 64 |
Ireland | 64 |
Australia | 47 |
China | 28 |
Germany | 22 |
France | 16 |
South Korea | 16 |
India | 11 |
Top cities views
Views | |
---|---|
Dublin | 63 |
Sydney | 42 |
Hangzhou | 21 |
Varberg | 14 |
Ashburn | 13 |
Solna | 10 |
Stockholm | 8 |
Cerritos | 6 |
Helsinki | 6 |
Bromma | 5 |